Jupiter Acquisition Corporation (JAQC) to Combine with Filament Health in $210M Deal

Jupiter (NASDAQ:JAQC) has entered into a definitive agreement to combine with psychedelic drug developer Filament Health (OTCQB:FLHLF) at an enterprise value of $210 million. Vancouver-based Filament is developing a line of psilocybin-based drug candidates and licensing its patents to a number of other biotech firms. The combined company is expected to trade on the Nasdaq
Read More